Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 29-37 , March 2007

Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?

  • Richard A. Larson, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationAddress: Section of Hematology/Oncology, University of Chicago Pritzker School of Medicine, MC-2115, 5841 South Maryland Avenue, Chicago, IL 60637, USA. Tel.: +1 773 702 6783 Fax: +1 773 702 3002.

References 

  1. Preisler HD. Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML. Cancer Treatment and Research. 2001;108:185–230
  2. Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. Haematologica. 1999;84:937–945
  3. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology. 1999;17:3835–3849
  4. Brunning RD, Matutes E, Harris NL, et al. Acute myeloid leukemia. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001;p. 88–89
  5. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. In:  Nimer Stephen D,  Golde David W editor. Hematologic Complications of Cancer. Hematology/Oncology Clinics of North America. 10:1996;p. 293–320
  6. Godley LA, Larson RA. The syndrome of therapy-related myelodysplasia and myeloid leukemia. In:  Bennett John M editors. The Myelodysplastic Syndromes. Pathobiology and Clinical Management. New York: Marcel Dekker; 2002;p. 139–176
  7. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004;104:822–828
  8. Lan Q, Zhang L, Li G, et al. Hematotoxicity in workers exposed to low levels of benzene. Science. 2004;306:1774–1776
  9. Rinsky RA, Smith AB, Hornung R, et al. Benzene and leukemia. An epidemiologic risk assessment. The New England Journal of Medicine. 1987;316:1044–1050
  10. Henshaw DL, Eatough JP, Richardson RB. Radon as a causative factor in induction of myeloid leukaemia and other cancers. Lancet. 1990;335:1008–1012
  11. Crane MM, Strom SS, Halabi S, et al. Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. Cancer Epidemiology, Biomarkers and Prevention. 1996;5:639–644
  12. Gajewski JL, Ho WG, Nimer SD, et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. Journal of Clinical Oncology. 1989;7:1637–1645
  13. Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. Journal of Clinical Oncology. 2003;21:256–265
  14. Goasguen JE, Matsuo T, Cox C, et al. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia. 1992;6:520–525
  15. Bennett JM. Morphologic dysplasia in acute myeloid leukemia: importance of granulocytic dysplasia. Journal of Clinical Oncology. 2003;21:3004
  16. Haferlach T, Kern W, Schoch C, et al. Morphologic dysplasia in acute myeloid leukemia: importance of garnulcytic dysplasia. Journal of Clinical Oncology. 2003;21:3004–3005
  17. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML10 trial. Blood. 1998;92:2322–2333
  18. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–1320
  19. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43–52
  20. Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18:120–125
  21. Kern W, Haferlach T, Schnittger S, et al. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. Journal of Clinical Oncology. 2004;22:2510–2511
  22. Andersen MK, Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood. 2002;100:1928–1929
  23. Andersen MK, Larson RA, Mauritzson N, et al. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33:395–400

PII: S1521-6926(06)00075-2

doi: 10.1016/j.beha.2006.10.006

Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 29-37 , March 2007

Article Tools

* Image Usage & Resolution